HighTower Advisors’s Aimmune Therapeutics AIMT Stock Holding History

HighTower Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-291,600	Closed	-$14K	–	3057
2020 Q3	$14K	Buy	291,600 +241,600	+483%	+$5.15M	﹤0.01%	2398
2020 Q2	$88K	Buy	50,000 +34,000	+213%	+$577K	﹤0.01%	2142
2020 Q1	$41K	Sell	16,000 -38,200	-70%	-$976K	﹤0.01%	2027
2019 Q4	$101K	Buy	+54,200	New	+$1.52M	﹤0.01%	2077

HighTower Advisors's AIMT Position: Q4 2020 in Review

HighTower Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 11,461 shares — an estimated $395K sold.

HighTower Advisors first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $395K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

HighTower Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
HighTower Advisors sold 11,461 Aimmune Therapeutics shares in Q4 2020, an estimated $395K.
HighTower Advisors first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
HighTower Advisors's Aimmune Therapeutics position peaked at $395K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.